With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
Bristol-Myers and AstraZeneca’s acquisition of Amylin as part of a 50-50 collaboration brings a big new player into the fast-growing GLP-1 class, which is emerging as a key component of treatment in the large, but highly competitive Type 2 diabetes market.
You may also be interested in...
GSK’s Tanzeum Once-Weekly GLP-1 To Launch In Third Quarter
FDA requires post-marketing studies to identify any cases of medullary thyroid cancer related to the drug and evaluate cardiovascular risk; GSK touts Tanzeum’s sustained glycemic effect, tolerability and its potential use as an alternative to insulin.
Repurposing Leptin: How a “Fat Drug” Became a Model for a Leaner Industry
Two decades ago, the “fat dissolving” protein leptin was touted as one of the biggest opportunities in biotech—based on preclinical rodent studies. The compound may finally be making it to market in a very different model: as an orphan drug sponsored by Big Pharma.
On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes
With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.